Health Trials

About this trial

The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.

Eligibility criteria

Qualifiers

Males and females of all races between 18 and 60 years of age

Obesity defined as body mass index between 30-40 kg/m2

Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score >2.2

Hypertension defined by two or more properly measured seated blood pressure readings >130/85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension.

Disqualifiers

Pregnancy or breast-feeding

Current smokers or history of heavy smoking (>2 packs/day)

History of alcohol or drug abuse

Morbid obesity (BMI > 40 kg/m2)

Trial design

Treatments tested in this trial

  • Angiotensin-(1-7)
  • Saline

Treatment groups

26 Participants
are divided into 2 treatment groups

Locations

1
Vanderbilt University Medical Center37232, NashvilleTennessee, United States

Sponsors and collaborators

Vanderbilt University

Lead sponsor

Source ClinicalTrials.gov